Core Insights - Brown Capital Management's Small Company Fund underperformed in Q4 2025, with a decline of 1.50% compared to the Russell 2000® Growth index's gain of 1.22% [1] - The Fund's performance for the entire year of 2025 was down 11.46%, significantly lagging behind the Index's return of 13.01% [1] - The Fund's investment strategy is based on company fundamentals, which showed strong revenue and earnings growth in 2025 [1] Company Focus: Veeva Systems Inc. - Veeva Systems Inc. (NYSE:VEEV) is a technology company providing a cloud-based software platform for the life sciences industry, with a market capitalization of $29.64 billion [2] - The stock of Veeva Systems Inc. experienced a one-month return of -19.57% and a 52-week decline of 20.26% [2] - Veeva Systems was identified as a detractor from the Fund's performance in Q4 2025, despite its strong market position and innovative solutions in the life sciences sector [3] - The company's offerings include Veeva Customer Relationship Management (CRM) and Veeva Vault, which have established a dominant market position and present opportunities for growth in clinical applications [3] - Veeva's client base includes major global pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Eli Lilly, Merck, and Novartis [3]

Key Takeaways AstraZeneca posted 8% revenue and 11% core EPS growth in 2025, led by 16 blockbusters.AZN guides mid-to-high single-digit 2026 revenue growth and targets $80B sales by 2030.Pfizer faces COVID declines and a 2026 LOE hit, with sales and EPS seen falling next year.Pfizer (PFE) and AstraZeneca (AZN) are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company revenues. Beyond cancer therapies ...

UK's RELX plans pay boost for CEO Engstrom, Sky News reports | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[AstraZeneca PLC]Follow[Relx PLC]Follow[Rolls-Royce Holdings PLC]FollowShow more companiesFeb 18 (Reuters) - British information group RELX [(REL.L), opens new tab] is preparing to grant its top boss, Erik Engstrom, a substantial pay rise, bringing it closer to its FTSE-100 peers like AstraZeneca [(AZN.L), opens n ...

Core Insights - As of February 18, 2026, three stocks in the health care sector are identified as potentially overbought, signaling a warning for momentum-focused investors [1]. Group 1: Overbought Stocks - AstraZeneca plc (NYSE:AZN) is listed among the major overbought players in the health care sector [2]. - Masimo Corp (NASDAQ:MASI) is also highlighted as one of the stocks that may be overvalued [2]. - Geron Corp (NASDAQ:GERN) completes the list of stocks that could be flashing warning signs for investors [2].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

As I’ve covered in the past , I was bullish on NN Group ( NNGPF ) ( NNGRY ) since mid-2024 due to an interesting combination of a high-dividend yield and relatively cheap valuation. However, following aLabutes IR is a Fund Manager/Analyst specialized in the financial sector, with more than 18 years of experience in the financial markets. I have worked at several type of institutions in the industry, always at the buy side and related to portfolio management. Associated with the existing author The Outsider. ...

Core Viewpoint - EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy and launch readiness for DURAVYU, an investigational treatment for retinal diseases currently in Phase 3 development [1][2] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate DURAVYU expected to provide significant commercial potential [8][9] - The company is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts [9] Leadership Appointment - Michael Campbell brings over 30 years of commercial leadership experience, having successfully launched several ophthalmology products, including Lucentis and Xiidra [1][3][4] - His previous roles include Chief Commercial Officer at Opthea and Senior Vice President at Viatris Eye Care, where he led the launch of Tyrvaya [3][4] Product Development - DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with topline data expected in mid-2026 [8][10] - The product is designed as a sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, and is positioned to potentially be the first sustained release TKI to market [2][8] Commercial Strategy - The company aims to leverage Campbell's expertise to position DURAVYU for a successful U.S. launch, emphasizing a patient-centric approach and robust clinical data [2][8] - DURAVYU is expected to address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME, enhancing its potential market impact [10]

Economic Outlook - The Bank of England is urged to implement quick interest rate cuts to alleviate the cost-of-living crisis and boost consumer spending and business confidence [1][2] - Trade unions support interest rate cuts, citing easing inflation as beneficial for working families, with expectations of further softening due to government support for energy bills and other costs [2] - Firms are looking for inflation easing to be accompanied by measures to reduce business costs, such as business rates reform, to stimulate economic growth [3] Inflation and Interest Rates - The Consumer Price Index (CPI) has dropped to 3.0%, the lowest level in nearly a year, indicating potential for interest rate cuts by the Bank of England [25][28] - Analysts predict a 25 basis point cut in interest rates at the next Bank of England meeting, with further cuts anticipated if inflation continues to decline [19][21][20] - Despite the drop in headline inflation, services inflation remains sticky, suggesting caution from the Monetary Policy Committee [22] Market Performance - The FTSE 100 index has reached new record highs, driven by gains in sectors such as mining, defense, and banking [6][15][28] - BAE Systems has reported a 10% increase in sales to £30.7 billion and a record order book of £83.6 billion, reflecting strong demand in the defense sector [23][10] - Glencore's revenue for 2025 increased by 7% to $247.54 billion, with adjusted EBIT falling less than expected, indicating resilience in the mining sector [16][17] Company-Specific Developments - BAE Systems has increased its dividend by 10% and expects sales growth of 7-9% for the current year, supported by rising global defense spending [23][13] - Glencore's performance improved significantly in the second half of the year, aided by stronger metals prices and higher copper output [17] - BAE's free cash flow is projected to exceed £1.3 billion, contributing to a reduction in net debt by 22% [13][24]

Market Overview - European stocks closed mostly higher, with the pan-European Stoxx 600 gaining 0.45% and the U.K.'s FTSE 100 climbing 0.79% [2] - Investors are optimistic about potential monetary easing from central banks, particularly the Bank of England, amid rising unemployment rates in the UK [1][9] Sector Performance - Defense stocks showed weakness due to hopes of de-escalation in U.S.-Iran tensions [3] - In the UK market, several companies such as Coca-Cola Europacific Partners, Barratt Redrow, and AstraZeneca saw gains between 2% and 3.5% [3] - Conversely, miners like Endeavour Mining and Antofagasta fell between 2% and 4% [4] Notable Company Movements - GSK's shares rose over 2.5% following the announcement of a £2 billion share buyback program [3] - Bayer in Germany soared more than 8%, while other companies like Vonovia and Infineon gained approximately 4% and 3.25% respectively [4] - In France, Dassault Systemes climbed about 4%, with other firms like Unibail Rodamco and AXA gaining 2%-3% [6] Economic Indicators - German consumer price inflation rebounded to 2.1% in January, influenced by higher food and services costs [7] - The UK's jobless rate increased to 5.2% in the fourth quarter, with average earnings growth at 4.2%, below expectations [9]

Core Viewpoint - Wall Street's major market averages ended near even as traders processed the latest retail inflation data [1] Market Performance - The blue-chip Dow ended with a gain of +0.1% [1] - The benchmark S&P 500 finished flat, showing no significant change [1] - The tech-focused Nasdaq Composite experienced a decline of -0.2% [1]